Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | CRHBP | P24387 | 2/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15779058 | 0.86 | GAA (0.51) | GAACYP46A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25256914 | 0.83 | CA12 (0.61) | GAACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2818982 | 0.83 | KDM4E (0.53) | GAACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1308471 | 0.81 | ABL1 (0.54) | GAACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1110936 | 0.81 | HPGD (0.53) | GAACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27726722 | 0.81 | NR4A2 (0.48) | GAACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4316682 | 0.81 | CYP1A2 (0.56) | GAACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4208170 | 0.81 | GAA (0.56) | GAACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29746327 | 0.81 | NR4A2 (0.48) | GAACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1696791 | 0.80 | CSNK2A1 (0.55) | ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | claimed |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| WO-2024061340-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-03-28 | — | — | WO | disclosed |
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-16 | — | — | US | disclosed |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2022-09-06 | — | — | US | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| CN-109219606-B | Halogen substituted piperidines as orexin receptor modulators | 阿斯利康(瑞典)有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-6908919-B2 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1202975-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORP (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6664255-B1 | 1-alkylamido-3-amino substituted; inhibiting serine proteases | PHARMACIA CORPORATION | 2003-12-16 | — | — | US | disclosed |
| EP-1292579-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1202975-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001087854-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069834-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | GAA 1404/4885CYP46A1 628/4885CYP1A2 859/4885 |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | GAA 3156/4885CYP46A1 1317/4885CYP1A2 1868/4885 |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | GAA 2206/4885CYP46A1 2002/4885CYP1A2 2948/4885 |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | GAA 1197/4885CYP46A1 632/4885CYP1A2 836/4885 |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | GAA 2206/4885CYP46A1 2002/4885CYP1A2 2948/4885 |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | GAA 225/4885CYP46A1 1423/4885CYP1A2 593/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | GAA 2206/4885CYP46A1 2002/4885CYP1A2 2948/4885 |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PRSS1, SERPINC1, SERPINE1 | GAA 777/4885CYP46A1 728/4885CYP1A2 2190/4885 |
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | GAA 579/4885CYP46A1 80/4885CYP1A2 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.